AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.047

+0.0024.44%

Volume:8.70M

Turnover:404.40K

Market Cap:69.26M

PE:-0.87

High:0.048

Open:0.045

Low:0.044

Close:0.045

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:0.41

T/O Rate:0.71%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.054

ROE:-77.31%

ROA:-42.45%

PB:1.13

PE(LYR):-0.87

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.31%

Capital Flow

Inflow:

Outflow:

News

Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says

MT Newswires Live

Immutep Gets a New Bull at Jefferies

Immutep - to Focus Efti Development on Hnscc with CPS < 1 and Neoadjuvant Sts

THOMSON REUTERS

Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/IMM.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.047,"timestamp":1789539120000,"preClose":0.045,"halted":0,"volume":8697659,"delay":0,"changeRate":0.04444444444444449,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"Closed","change":0.002,"latestTime":"09-16 16:12:00 AEST","open":0.045,"high":0.048,"low":0.044,"amount":404401,"amplitude":0.088889,"askPrice":0.047,"askSize":7192,"bidPrice":0.046,"bidSize":113636,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.045,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.409386,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.045,"auctionPrice":0.047,"auctionVolume":727381,"auctionTime":1789539016497,"referencePrice":0.047,"referenceTime":1789540920650,"auction":3,"marketStatus":"盘后竞价","timestamp":1789539016497}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":0.409386,"shares":1473721306,"dividePrice":0,"high":0.048,"amplitude":0.088889,"preClose":0.045,"low":0.044,"week52Low":0.028,"pbRate":"1.13","psRate":"3.47","week52High":0.47,"institutionHeld":0,"latestPrice":0.047,"committee":0.880955,"eps":-0.0539,"divideRate":0,"volume":8697659,"delay":0,"ttmEps":-0.0539,"open":0.045,"prevYearClose":0.415,"prevWeekClose":0.056,"prevMonthClose":0.048,"prevQuarterClose":0.053,"fiveDayClose":0.046,"twentyDayClose":0.051,"sixtyDayClose":0.052,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667616451","title":"Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616451","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616451?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:33","pubTimestamp":1789450429,"startTime":"0","endTime":"0","summary":"Immutep's  eftilagimod alfa drug candidate, or efti, now has a clearer potential development path after the early termination of the TACTI-004 study, according to a Tuesday note by Jefferies.Its root cause analysis increasingly supports TACTI-004 as a potentially isolated product-specific structural issue rather than a failure of efti's biology. The identification of subtle N-glycan differences in the efti material used in TACTI-004 is potentially important.With prior efti data intact, head and neck squamous cell carcinoma prioritization, fast-track status, and planned manufacturing work, the risk and reward look more constructive despite residual execution risk.The brokerage upgraded its rating on Immutep to buy from hold with the price target rising to AU$0.08 per share from AU$0.04.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667692474","title":"Immutep Gets a New Bull at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2667692474","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667692474?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:09","pubTimestamp":1789434540,"startTime":"0","endTime":"0","summary":"0109 GMT - Immutep gets a new bull at Jefferies, where analyst David Stanton sees a clearer potential development path for the biotechnology company's lead product candidate. Raising his recommendation to buy from hold, Stanton is encouraged by the Australian company's update that the early discontinuation of a lung cancer study doesn't appear to be linked to clinical factors or trial execution. Emerging evidence supports a cautiously constructive view that the outcome stemmed from an isolated manufacturing or product-characterisation issue, Stanton explains in a note to clients. Risk/reward looks more constructive to Stanton, who now includes Immutep's phase IIhead and neck squamous cell carcinoma opportunity in his valuation. Jefferies doubles its target price to 8 Australian cents. Shares are flat at 4.7 Australian cents.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMP","IMM.AU","BK7067","BK4139","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666521234","title":"Immutep - to Focus Efti Development on Hnscc with CPS < 1 and Neoadjuvant Sts","url":"https://stock-news.laohu8.com/highlight/detail?id=2666521234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666521234?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666212615","title":"Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666212615?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":15,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMM.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.003125}]}}